Real-World Evidence, HEOR, Precision Medicine, and More
The practice of health care consulting continues to evolve at a rapid pace. The use of real-world evidence (RWE) to complement clinical trial results is expanding, requiring new applications of data science methods and new approaches to determining value. Similarly, breakthroughs in precision medicine call for different ways of predicting long-term value and tailoring payment strategies for innovative therapies. Along with other topics, this issue of Health Care Bulletin covers some of the ways in which groundbreaking tools are transforming a familiar landscape.
In this issue:
With advanced statistical approaches, health care scientists can extract knowledge from what might otherwise be unmanageable datasets and sources of information.
A key question for payers is whether a drug works as well in the real world as it did in the controlled environment of a clinical trial.
Real-world evidence (RWE) is gaining prominence in the drug approval process for promising and breakthrough treatments.
The development of novel cancer therapies with curative potential has spurred the need for alternatives to traditional survival models for predicting long-term value.
Important breakthroughs have occurred in the area of precision medicine in the past several years.
To realize the clinical benefits of gene therapy, “outside the box” payment models may be needed.
Analysis Group helped organize a conference with more than 100 government officials, academics, and industry stakeholders from around the world to discuss medical big data, health economics, and health technology assessment (HTA) research.
Also in this Issue
Recent Health Care News & Events
Analysis Group is pleased to highlight two new academic affiliates whose credentials in life sciences augment our core strengths.
Craig Garthwaite; Herman R. Smith Research Professor in Hospital and Health Services Management, Associate Professor of Strategy and Director of Healthcare at Kellogg, Kellogg School of Management at Northwestern University
Anupam B. Jena; Ruth L. Newhouse Associate Professor of Health Care Policy at Harvard Medical School; Physician, Department of Medicine, Massachusetts General Hospital
Videos: A Diverse Health Care Practice
When clients are facing challenges with a health care component, they count on Analysis Group’s unique ability to build a diverse team to address every aspect of the question at hand. Drawing on our Health Care group’s expertise, we provide assistance with matters related to HEOR; epidemiology and drug safety; market access, pricing/contracting, and commercial strategy; litigation; and public policy assessments.
Analysis Group at 2018 Conferences
Analysis Group contributed to the following major conferences through participation in symposiums and panels, poster presentations, and sponsorships. Some of the conferences listed include links to more detailed summaries on the website.
Alzheimer’s Association International Conference 2018
Seventh Conference of the American Society of Health Economists (ASHEcon)
ISPOR Boston Chapter